Nova Mentis Life Science Corp. (NMLSF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 841.66 Thousand CAD | 229.49% |
| 2022 | 255.44 Thousand CAD | -39.48% |
| 2021 | 422.05 Thousand CAD | 10.21% |
| 2020 | 382.96 Thousand CAD | 17.81% |
| 2019 | 325.07 Thousand CAD | 5.22% |
| 2018 | 308.95 Thousand CAD | 94.11% |
| 2017 | 159.16 Thousand CAD | 108.06% |
| 2016 | 76.5 Thousand CAD | -26.59% |
| 2015 | 104.21 Thousand CAD | -29.46% |
| 2014 | 147.74 Thousand CAD | -53.42% |
| 2013 | 317.15 Thousand CAD | -6.67% |
| 2012 | 339.82 Thousand CAD | 1274.12% |
| 2011 | 24.73 Thousand CAD | -69.15% |
| 2010 | 80.17 Thousand CAD | -7.12% |
| 2009 | 86.32 Thousand CAD | 26.67% |
| 2008 | 68.14 Thousand CAD | 242.84% |
| 2007 | 19.87 Thousand CAD | -65.23% |
| 2006 | 57.16 Thousand CAD | 1363.19% |
| 2005 | 3907.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 995.07 Thousand CAD | 18.23% |
| 2024 Q2 | 1.07 Million CAD | 7.72% |
| 2023 FY | 841.66 Thousand CAD | 229.49% |
| 2023 Q3 | 654.93 Thousand CAD | 36.88% |
| 2023 Q1 | 343.45 Thousand CAD | 34.46% |
| 2023 Q4 | 841.66 Thousand CAD | 28.51% |
| 2023 Q2 | 478.45 Thousand CAD | 39.31% |
| 2022 Q3 | 224.86 Thousand CAD | 36.95% |
| 2022 FY | 255.44 Thousand CAD | -39.48% |
| 2022 Q1 | 288.18 Thousand CAD | -31.72% |
| 2022 Q2 | 164.18 Thousand CAD | -43.03% |
| 2022 Q4 | 255.44 Thousand CAD | 13.6% |
| 2021 Q1 | 254.09 Thousand CAD | -33.65% |
| 2021 Q2 | 294.88 Thousand CAD | 16.05% |
| 2021 Q3 | 656.55 Thousand CAD | 122.64% |
| 2021 Q4 | 422.05 Thousand CAD | -35.72% |
| 2021 FY | 422.05 Thousand CAD | 10.21% |
| 2020 Q1 | 271.04 Thousand CAD | -16.62% |
| 2020 Q4 | 382.96 Thousand CAD | 32.01% |
| 2020 FY | 382.96 Thousand CAD | 17.81% |
| 2020 Q3 | 290.1 Thousand CAD | 10.71% |
| 2020 Q2 | 262.03 Thousand CAD | -3.33% |
| 2019 Q3 | 333.06 Thousand CAD | -7.71% |
| 2019 Q4 | 325.07 Thousand CAD | -2.4% |
| 2019 FY | 325.07 Thousand CAD | 5.22% |
| 2019 Q1 | 281.91 Thousand CAD | -8.75% |
| 2019 Q2 | 360.86 Thousand CAD | 28.0% |
| 2018 Q4 | 308.95 Thousand CAD | 3.28% |
| 2018 Q3 | 299.14 Thousand CAD | 84.5% |
| 2018 Q2 | 162.13 Thousand CAD | -10.48% |
| 2018 Q1 | 181.11 Thousand CAD | 13.79% |
| 2018 FY | 308.95 Thousand CAD | 94.11% |
| 2017 Q1 | 109.4 Thousand CAD | 43.02% |
| 2017 Q4 | 159.16 Thousand CAD | 105.42% |
| 2017 Q3 | 77.48 Thousand CAD | -17.87% |
| 2017 FY | 159.16 Thousand CAD | 108.06% |
| 2017 Q2 | 94.34 Thousand CAD | -13.77% |
| 2016 Q2 | 84.82 Thousand CAD | -25.97% |
| 2016 FY | 76.5 Thousand CAD | -26.59% |
| 2016 Q3 | 201.96 Thousand CAD | 138.1% |
| 2016 Q1 | 114.59 Thousand CAD | 9.96% |
| 2016 Q4 | 76.5 Thousand CAD | -62.12% |
| 2015 Q1 | 108.45 Thousand CAD | -26.59% |
| 2015 Q4 | 104.21 Thousand CAD | -37.69% |
| 2015 Q3 | 167.24 Thousand CAD | 17.95% |
| 2015 Q2 | 141.79 Thousand CAD | 30.75% |
| 2015 FY | 104.21 Thousand CAD | -29.46% |
| 2014 Q3 | 146.36 Thousand CAD | -45.2% |
| 2014 Q1 | 263.25 Thousand CAD | -16.99% |
| 2014 FY | 147.74 Thousand CAD | -53.42% |
| 2014 Q4 | 147.74 Thousand CAD | 0.94% |
| 2014 Q2 | 267.11 Thousand CAD | 1.46% |
| 2013 Q1 | 253.03 Thousand CAD | -25.54% |
| 2013 Q2 | 257.67 Thousand CAD | 1.83% |
| 2013 Q3 | 321.05 Thousand CAD | 24.6% |
| 2013 FY | 317.15 Thousand CAD | -6.67% |
| 2013 Q4 | 317.15 Thousand CAD | -1.21% |
| 2012 Q4 | 339.82 Thousand CAD | 57.96% |
| 2012 Q2 | 146.19 Thousand CAD | 137.32% |
| 2012 Q1 | 61.6 Thousand CAD | 149.1% |
| 2012 FY | 339.82 Thousand CAD | 1274.12% |
| 2012 Q3 | 215.13 Thousand CAD | 47.16% |
| 2011 FY | 24.73 Thousand CAD | -69.15% |
| 2011 Q4 | 24.73 Thousand CAD | -9.53% |
| 2011 Q3 | 27.33 Thousand CAD | -39.23% |
| 2011 Q2 | 44.97 Thousand CAD | -49.46% |
| 2011 Q1 | 88.99 Thousand CAD | 11.0% |
| 2010 Q4 | 80.17 Thousand CAD | -63.42% |
| 2010 Q1 | 24.73 Thousand CAD | -71.35% |
| 2010 Q2 | 118.4 Thousand CAD | 378.77% |
| 2010 Q3 | 219.19 Thousand CAD | 85.11% |
| 2010 FY | 80.17 Thousand CAD | -7.12% |
| 2009 FY | 86.32 Thousand CAD | 26.67% |
| 2009 Q4 | 86.32 Thousand CAD | -64.47% |
| 2009 Q3 | 242.95 Thousand CAD | -19.45% |
| 2009 Q2 | 301.61 Thousand CAD | 4.36% |
| 2009 Q1 | 289.01 Thousand CAD | 324.09% |
| 2008 Q2 | 105.85 Thousand CAD | 553.99% |
| 2008 FY | 68.14 Thousand CAD | 242.84% |
| 2008 Q1 | 16.18 Thousand CAD | -18.57% |
| 2008 Q3 | 32.25 Thousand CAD | -69.53% |
| 2008 Q4 | 68.14 Thousand CAD | 111.31% |
| 2007 FY | 19.87 Thousand CAD | -65.23% |
| 2007 Q3 | 14.75 Thousand CAD | -67.65% |
| 2007 Q4 | 19.87 Thousand CAD | 34.74% |
| 2007 Q2 | 45.6 Thousand CAD | -3.8% |
| 2007 Q1 | 47.4 Thousand CAD | -17.08% |
| 2006 Q3 | 90.56 Thousand CAD | 563.89% |
| 2006 Q4 | 57.16 Thousand CAD | -36.88% |
| 2006 FY | 57.16 Thousand CAD | 1363.19% |
| 2006 Q2 | 13.64 Thousand CAD | 0.0% |
| 2005 FY | 3907.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 98.421% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 91.216% |
| SQZ Biotechnologies Company | 50.03 Million USD | 98.318% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.839% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.574% |
| Mesoblast Limited | 188.44 Million USD | 99.553% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 78.147% |
| Genus plc | 485 Million USD | 99.826% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 85.594% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 66.552% |
| Marizyme, Inc. | 26.67 Million USD | 96.845% |
| ContraFect Corporation | 32.53 Million USD | 97.413% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 77.851% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 57.52% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 78.011% |
| Intellipharmaceutics International Inc. | 12 Million USD | 92.991% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 92.854% |
| MultiCell Technologies, Inc. | 1617.67 USD | -51929.277% |
| Accustem Sciences Inc. | 1.07 Million USD | 22.013% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.913% |
| EV Biologics, Inc. | 2.11 Million USD | 60.206% |
| Q BioMed Inc. | 8.13 Million USD | 89.651% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.985% |
| Neon Bloom, Inc. | 1.22 Million USD | 31.361% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 83.644% |
| Biomind Labs Inc. | 1.49 Million USD | 43.837% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 99.655% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 95.427% |
| Skye Bioscience, Inc. | 14.07 Million USD | 94.019% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 58.129% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -492.323% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 91.109% |
| IMV Inc. | 37.93 Million USD | 97.781% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -318.496% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 85.352% |
| GB Sciences, Inc. | 5.41 Million USD | 84.464% |
| Alpha Cognition Inc. | 7.16 Million USD | 88.253% |
| HST Global, Inc. | 593.59 Thousand USD | -41.791% |
| CSL Limited | 18.62 Billion USD | 99.995% |
| Halberd Corporation | 728.71 Thousand USD | -15.499% |
| Enzolytics Inc. | 365.26 Million USD | 99.77% |
| Resverlogix Corp. | 67.39 Million USD | 98.751% |
| Affymax, Inc. | 8.87 Million USD | 90.512% |
| SYBLEU INC | 681.41 Thousand USD | -23.517% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -0.349% |
| argenx SE | 444.95 Million USD | 99.811% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.877% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 50.895% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 92.929% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 77.036% |
| AVAX Technologies, Inc. | 3.99 Million USD | 78.925% |
| Zenith Capital Corp. | 27.56 Thousand USD | -2952.929% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.937% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -252.67% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 77.461% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -23.622% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.291% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 90.692% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1157.545% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 41.301% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 98.326% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 68.961% |
| BioStem Technologies, Inc. | 15.9 Million USD | 94.708% |
| ONE Bio Corp. | 27.49 Million USD | 96.939% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -81.12% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -2968.064% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 33.159% |
| Agentix Corp. | 2.51 Million USD | 66.475% |
| LadRx Corporation | 2.2 Million USD | 61.752% |
| Cell Source, Inc. | 15.8 Million USD | 94.675% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -1783.081% |
| Regen BioPharma, Inc. | 5.45 Million USD | 84.578% |
| Regen BioPharma, Inc. | 5.45 Million USD | 84.578% |
| NovAccess Global Inc. | 7.86 Million USD | 89.293% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 96.599% |
| Itoco Inc. | 1.65 Million USD | 49.087% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 58.975% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 86.086% |
| Kadimastem Ltd | 3.5 Million USD | 75.986% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -99.65% |
| CytoDyn Inc. | 127.89 Million USD | 99.342% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -1913.594% |
| Mobile Lads Corp. | 1.31 Million USD | 35.922% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 46.267% |
| Qrons Inc. | 1.48 Million USD | 43.464% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 92.38% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -4.064% |
| Rebus Holdings, Inc. | 5.24 Million USD | 83.944% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 86.207% |
| International Stem Cell Corporation | 5.27 Million USD | 84.05% |
| Bioxytran, Inc. | 3.24 Million USD | 74.099% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -34.492% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 81.771% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 97.947% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 96.22% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 58.444% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 84.636% |
| Neutra Corp. | 973.52 Thousand USD | 13.545% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 97.099% |
| PureTech Health plc | 125.58 Million USD | 99.33% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 77.598% |
| IXICO plc | 1.9 Million USD | 55.709% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 95.9% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.185% |
| CSL Limited | 18.62 Billion USD | 99.995% |
| Cellectis S.A. | 249.36 Million USD | 99.662% |